Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

November 30, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
OTHER

Best Supportive Care (BSC)

BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.

DRUG

Panitumumab

Administered intravenously

Trial Locations (78)

1000

Research Site, Manila

1002

Research Site, Riga

1008

Research Site, Manila

1079

Research Site, Riga

1300

Research Site, Pasay

5417

Research Site, Daugavpils

6000

Research Site, Cebu City

8000

Research Site, Davao City

10000

Research Site, Zagreb

10400

Research Site, George Town

11000

Research Site, Belgrade

11522

Research Site, Athens

13419

Research Site, Tallinn

14080

Research Site, Mexico City

18000

Research Site, Niš

21000

Research Site, Split

21204

Research Site, Kamenitz

31000

Research Site, Osijek

50009

Research Site, Kaunas

51000

Research Site, Rijeka

51014

Research Site, Tartu

52100

Research Site, Pula

56000

Research Site, Kuala Lumpur

59100

Research Site, Kuala Lumpur

62290

Research Site, Cuernavaca

68000

Research Site, Oaxaca City

71800

Research Site, Kampung Baharu Nilai

73300

Research Site, Chania

100032

Research Site, Beijing

100337

Research Site, Ploieşti

110001

Research Site, Shenyang

130021

Research Site, Changchun

200233

Research Site, Shanghai

200385

Research Site, Craiova

200642

Research Site, Craiova

210029

Research Site, Nanjing

300167

Research Site, Timișoara

350001

Research Site, Fuzhou

350025

Research Site, Fuzhou

400006

Research Site, Cluj-Napoca

400015

Research Site, Cluj-Napoca

400037

Research Site, Chongqing

400042

Research Site, Chongqing

400058

Research Site, Cluj-Napoca

700106

Research Site, Lasi

710032

Research Site, Xi'an

710061

Research Site, Xi'an

720237

Research Site, Suceava

2520612

Research Site, Viña del Mar

4810469

Research Site, Temuco

80420-090

Research Site, Curitiba

59075-740

Research Site, Natal

98700-000

Research Site, Ijuí

90610-000

Research Site, Porto Alegre

J4V 2H1

Research Site, Greenfield Park

H1T 2M4

Research Site, Montreal

H4J 1C5

Research Site, Montreal

G1R 2J6

Research Site, Québec

G1S 4L8

Research Site, Québec

G8Z 3R9

Research Site, Trois-Rivières

050011

Research Site, Shijiazhuang

500 024

Research Site, Hyderabad

530 002

Research Site, Visakhapatnam

560 054

Research Site, Bangalore

682 304

Research Site, Kochi

400 012

Research Site, Mumbai

422 004

Research Site, Nashik

422 005

Research Site, Nashik

411 001

Research Site, Pune

600 018

Research Site, Chennai

08660

Research Site, Vilnius

06760

Research Site, Mexico City

022328

Research Site, Bucharest

022338

Research Site, Bucharest

410-769

Research Site, Goyang-si, Gyeonggi-do

120-752

Research Site, Seoul

135-710

Research Site, Seoul

138-736

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01412957 - Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter